Trial
NCT05983965
Study of Tazemetostat in Lymphoid Malignancies
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Alabama at Birmingham
Collaborators
Robert Award; Epizyme, Inc.
Condition
T-cell Lymphoma
Intervention
Tazemetostat
Why stopped
Ipsen, drug company requested all studies using the drug Taxemetostat be terminated due to increased risk of secondary malignancies in subjects.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-17